Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purines and pyrimidines needed for DNA and RNA, leading to reduced proliferation of immune cells and malignant lymphocytes, thereby exerting immunosuppressive and anticancer effects.

The dose of Metoject Pen is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal function, and response to therapy. Patients should follow the exact dosing regimen provided by their healthcare professional.

Metoject Pen is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations or death. It is also not recommended during breastfeeding, as methotrexate can be transferred to the infant through milk.

To order Metoject Pen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Both methotrexate (Metoject Pen) and leflunomide are DMARDs used for rheumatoid arthritis, but methotrexate is generally considered first‑line due to extensive clinical experience and efficacy data. Leflunomide may be used when methotrexate is intolerable or contraindicated, though it carries its own hepatic and teratogenic risks.

Metoject Pen should be stored at 2‑8 °C (refrigerated). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking the device. Do not use the pen if it has been exposed to temperatures outside this range.

Metoject Pen is a pre‑filled, single‑use device for subcutaneous injection. After confirming the correct dose, the pen is placed against the skin (commonly the abdomen or thigh), the needle is activated, and the medication is delivered over a few seconds. Patients should be trained by a healthcare professional on proper technique.

The most serious adverse events include severe liver toxicity, pulmonary fibrosis or interstitial pneumonitis, and profound bone‑marrow suppression leading to pancytopenia. These conditions require immediate medical attention and may necessitate discontinuation of therapy.

Metoject Pen should be avoided in pregnant women, breastfeeding mothers, patients with severe renal or hepatic impairment, those with known hypersensitivity to methotrexate, and individuals receiving live vaccines. Clinicians must also assess risk in elderly patients and those with pre‑existing lung disease.